Helle Katrine Knutsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Helle Katrine Knutsen has a total of 321 co-authors. Here are the top co-authors by number of shared publications:
- Anne Lise Brantsæter
Department of Food Safety, Norwegian Institute of Public Health, Oslo, Norway
26 shared publications - Helle Margrete Meltzer
Norwegian Institute of Public Health
26 shared publications Jan Alexander
Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway
23 shared publications- Margaretha Haugen
Department of Exposure and Risk Assessment, Norwegian Institute of Public Health, Oslo, Norway
20 shared publications - Helen Engelstad Kvalem
Norwegian Institute of Public Health, Oslo, Norway
16 shared publications Cathrine Thomsen
Department of Environmental Exposure and Epidemiology, Norwegian Institute of Public Health, Oslo, Norway
8 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Elsevier in Environment International
- Vol. 217
Strategy for mixture risk assessment using European human biomonitoring data: lessons learned from applications to pesticides, per- and polyfluoroalkyl substances and metal(loid)s
- 21 October 2026
- Published by Elsevier in Environment International
- Vol. 217
Open AccessStrategy for mixture risk assessment using European human biomonitoring data: lessons learned from applications to pesticides, per- and polyfluoroalkyl substances and metal(loid)s
- Open Access
- 12 October 2026
- Published by Elsevier in International Journal of Hygiene and Environmental Health
- Vol. 279
Health-related interpretation of human biomonitoring results – new and updated human biomonitoring guidance values from PARC and HBM4EU
- 12 October 2026
- Published by Elsevier in International Journal of Hygiene and Environmental Health
- Vol. 279
Open AccessHealth-related interpretation of human biomonitoring results – new and updated human biomonitoring guidance values from PARC and HBM4EU
- Top Cited PapersOpen Access
- 1 September 2024
- Published by Wiley in EFSA Journal
- Vol. 22 (9) , e8961
Guidance on the scientific requirements for an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283
The European Commission requested EFSA to update the scientific guidance for the preparation of applications for authorisation of novel foods, previously developed following the adoption of Regulation (EU) 2015/2283 on novel foods. This guidance document provides advice on the scientific information needed to be submitted by the applicant towards demonstrating the safety of the novel food. Requirements pertain to the description of the novel food, production process, compositional data, specifications, proposed uses and use levels and anticipated intake of the novel food. Furthermore, information needed in sections on the history of use of the novel food and/or its source, absorption, distribution, metabolism, excretion, toxicological information, nutritional information and allergenicity is also described. The applicant should integrate and interpret the data presented in the different sections to provide their overall considerations on how the information supports the safety of the novel food under the proposed conditions of use. Where potential health hazards have been identified, they are to be discussed in relation to the anticipated intake of the novel food and the proposed target populations. On the basis of the information provided, EFSA will assess the safety of the novel food under the proposed conditions of use.
- 1 September 2024
- Published by Wiley in EFSA Journal
- Vol. 22 (9) , e8961
Top Cited PapersOpen AccessGuidance on the scientific requirements for an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283
The European Commission requested EFSA to update the scientific guidance for the preparation of applications for authorisation of novel foods, previously developed following the adoption of Regulation (EU) 2015/2283 on novel foods. This guidance document provides advice on the scientific information needed to be submitted by the applicant towards demonstrating the safety of the novel food. Requirements pertain to the description of the novel food, production process, compositional data, specifications, proposed uses and use levels and anticipated intake of the novel food. Furthermore, information needed in sections on the history of use of the novel food and/or its source, absorption, distribution, metabolism, excretion, toxicological information, nutritional information and allergenicity is also described. The applicant should integrate and interpret the data presented in the different sections to provide their overall considerations on how the information supports the safety of the novel food under the proposed conditions of use. Where potential health hazards have been identified, they are to be discussed in relation to the anticipated intake of the novel food and the proposed target populations. On the basis of the information provided, EFSA will assess the safety of the novel food under the proposed conditions of use.
- Open Access
- 14 July 2024
- Published by Elsevier in Science of The Total Environment
- Vol. 947, 174550
Low levels of per- and polyfluoroalkyl substances (PFAS) detected in drinking water in Norway, but elevated concentrations found near known sources
- 14 July 2024
- Published by Elsevier in Science of The Total Environment
- Vol. 947, 174550
Open AccessLow levels of per- and polyfluoroalkyl substances (PFAS) detected in drinking water in Norway, but elevated concentrations found near known sources
- Open Access
- 24 August 2022
- Published by Wiley in EFSA Journal
- Vol. 20 (8) , e07452
Conversion of calcium‐l‐methylfolate and (6S)‐5‐methyltetrahydrofolic acid glucosamine salt into dietary folate equivalents
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver a scientific opinion on the conversion of calcium‐l‐methylfolate and (6S)‐5‐methyltetrahydrofolic acid glucosamine salt (collectively called 5‐MTHF hereafter) into dietary folate equivalents (DFE). Following a systematic review, the conclusions of the opinion are based on one intervention study in adults for intakes < 400 μg/day and three intervention studies in adults for intakes ≥ 400 μg/day. At intakes below 400 μg/day, folic acid (FA) is assumed to be linearly related to responses of biomarkers of intake and status and is an appropriate comparator for deriving a DFE conversion factor for 5‐MTHF. It is proposed to use the same factor as for folic acid for conversion of 5‐MTHF into DFE for intakes < 400 μg/day. As such intake levels are unlikely to be exceeded through fortified food consumption, the conversion factor of 1.7 relative to natural food folate (NF) could be applied to 5‐MTHF added to foods and to food supplements providing < 400 μg/day. At 400 μg/day, 5‐MTHF was found to be more bioavailable than folic acid and a conversion factor of 2 is proposed for this intake level and for higher intakes. The derived DFE equations are DFE = NF + 1.7 × FA + 1.7 × 5‐MTHF for fortified foods and food supplements providing intakes < 400 μg/day; and DFE = NF + 1.7 × FA + 2.0 × 5‐MTHF for food supplements providing intakes ≥ 400 μg/day. Although this assessment applies to calcium‐L‐methylfolate and 5‐MTHF glucosamine salt, it is considered that the influence of the cation on bioavailability is likely to be within the margin of error of the proposed DFE equations. Therefore, the proposed equations can also be applied to 5‐MTHF associated with other cations.
- 24 August 2022
- Published by Wiley in EFSA Journal
- Vol. 20 (8) , e07452
Open AccessConversion of calcium‐l‐methylfolate and (6S)‐5‐methyltetrahydrofolic acid glucosamine salt into dietary folate equivalents
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver a scientific opinion on the conversion of calcium‐l‐methylfolate and (6S)‐5‐methyltetrahydrofolic acid glucosamine salt (collectively called 5‐MTHF hereafter) into dietary folate equivalents (DFE). Following a systematic review, the conclusions of the opinion are based on one intervention study in adults for intakes < 400 μg/day and three intervention studies in adults for intakes ≥ 400 μg/day. At intakes below 400 μg/day, folic acid (FA) is assumed to be linearly related to responses of biomarkers of intake and status and is an appropriate comparator for deriving a DFE conversion factor for 5‐MTHF. It is proposed to use the same factor as for folic acid for conversion of 5‐MTHF into DFE for intakes < 400 μg/day. As such intake levels are unlikely to be exceeded through fortified food consumption, the conversion factor of 1.7 relative to natural food folate (NF) could be applied to 5‐MTHF added to foods and to food supplements providing < 400 μg/day. At 400 μg/day, 5‐MTHF was found to be more bioavailable than folic acid and a conversion factor of 2 is proposed for this intake level and for higher intakes. The derived DFE equations are DFE = NF + 1.7 × FA + 1.7 × 5‐MTHF for fortified foods and food supplements providing intakes < 400 μg/day; and DFE = NF + 1.7 × FA + 2.0 × 5‐MTHF for food supplements providing intakes ≥ 400 μg/day. Although this assessment applies to calcium‐L‐methylfolate and 5‐MTHF glucosamine salt, it is considered that the influence of the cation on bioavailability is likely to be within the margin of error of the proposed DFE equations. Therefore, the proposed equations can also be applied to 5‐MTHF associated with other cations.
- Open Access
- 1 May 2022
- Published by Wiley in EFSA Journal
- Vol. 20 (5) , e07137
Safety of bovine milk osteopontin as a Novel food pursuant to Regulation (EU) 2015/2283
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on bovine milk osteopontin (bmOPN) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF concerns OPN derived from bovine whey. The NF is intended to be used at a maximum use level of 151 mg/L, in infant formula (IF), follow‐on formula (FoF) and ready‐to‐eat dairy‐based meals for children up to 35 months of age. As compared to the concentrations naturally present in cow’s milk and concentrations found in IF on the market reported in the literature, the proposed use level of the NF represents an about 10‐fold higher concentration of bmOPN. The intended use levels of the NF would provide bmOPN at a concentration within the range of human milk (hm) OPN. In a 6‐month study, 14, 72 and 140 mg bmOPN/L in reconstituted (as consumed) IF were given to 279 infants in order to study possible effects on frequency and severity of adverse events, and growth, formula intake and stool consistency. Despite that a number of inconsistencies and limitations were noted in the study report, the Panel considers that the results obtained from this study do not raise safety concerns. Considering the source of the NF, that neither the toxicological studies nor the provided infant study do raise safety concerns, and the low bmOPN plasma levels in infants resulting from the consumption of the NF, the Panel considers that the margin of exposure (i.e. 36) between the NOAEL of the subchronic toxicity study (1,200 mg/kg bw per day) and the highest P95 estimate for infants (33.4 mg/kg bw per day) is sufficient. The Panel concludes that the NF is safe under the proposed conditions of use.
- 1 May 2022
- Published by Wiley in EFSA Journal
- Vol. 20 (5) , e07137
Open AccessSafety of bovine milk osteopontin as a Novel food pursuant to Regulation (EU) 2015/2283
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on bovine milk osteopontin (bmOPN) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF concerns OPN derived from bovine whey. The NF is intended to be used at a maximum use level of 151 mg/L, in infant formula (IF), follow‐on formula (FoF) and ready‐to‐eat dairy‐based meals for children up to 35 months of age. As compared to the concentrations naturally present in cow’s milk and concentrations found in IF on the market reported in the literature, the proposed use level of the NF represents an about 10‐fold higher concentration of bmOPN. The intended use levels of the NF would provide bmOPN at a concentration within the range of human milk (hm) OPN. In a 6‐month study, 14, 72 and 140 mg bmOPN/L in reconstituted (as consumed) IF were given to 279 infants in order to study possible effects on frequency and severity of adverse events, and growth, formula intake and stool consistency. Despite that a number of inconsistencies and limitations were noted in the study report, the Panel considers that the results obtained from this study do not raise safety concerns. Considering the source of the NF, that neither the toxicological studies nor the provided infant study do raise safety concerns, and the low bmOPN plasma levels in infants resulting from the consumption of the NF, the Panel considers that the margin of exposure (i.e. 36) between the NOAEL of the subchronic toxicity study (1,200 mg/kg bw per day) and the highest P95 estimate for infants (33.4 mg/kg bw per day) is sufficient. The Panel concludes that the NF is safe under the proposed conditions of use.
- Open Access
- 1 December 2021
- Published by Elsevier in Environment International
- Vol. 157, 106804
Urinary deoxynivalenol as a biomarker of exposure in different age, life stage and dietary practice population groups
- 1 December 2021
- Published by Elsevier in Environment International
- Vol. 157, 106804
Open AccessUrinary deoxynivalenol as a biomarker of exposure in different age, life stage and dietary practice population groups
- Open Access
- 1 April 2021
- Published by Elsevier in Reproductive Toxicology
- Vol. 101, 93-114
Does the food processing contaminant acrylamide cause developmental neurotoxicity? A review and identification of knowledge gaps
- 1 April 2021
- Published by Elsevier in Reproductive Toxicology
- Vol. 101, 93-114
Open AccessDoes the food processing contaminant acrylamide cause developmental neurotoxicity? A review and identification of knowledge gaps